Related Experiment Video
Updated: Apr 21, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
[Is rituximab effective for induction of remission in lupus nephritis?]
Macarena Mac-Namara1, Gabriel Rada2
1Programa de Salud Basada en Evidencia, Facultad de Medicina, Pontificia Universidad Católica de Chile; Departamento de Medicina Interna, Facultad de Medicina, Pontificia Universidad Católica de Chile. Address: Facultad de Medicina, Pontificia Universidad Católica de Chile, Lira 63, Santiago Centro, Chile.
The combination of cyclophosphamide and steroids constitutes the standard treatment in lupus nephritis requiring immunosuppressive therapy. However, it is associated with important adverse effects, so there is interest in alternative immunosuppressors such as rituximab. Searching in Epistemonikos database, which is maintained by screening 19 databases, we identified 5 systematic reviews including 24 studies. We combined the evidence using summary of findings tables following the GRADE approach and concluded there is uncertainty about the effects of rituximab in lupus nephritis because the certainty of the evidence is very low, probably leads to important adverse effects, and has high cost. Rituximab should not be used outside the context of a clinical trial, or only in cases where other treatments have failed and there are no resource constraints.
The combination of cyclophosphamide and steroids constitutes the standard treatment in lupus nephritis requiring immunosuppressive therapy. However, it is associated with important adverse effects, so there is interest in alternative immunosuppressors such as rituximab. Searching in Epistemonikos database, which is maintained by screening 19 databases, we identified 5 systematic reviews including 24 studies. We combined the evidence using summary of findings tables following the GRADE approach and concluded there is uncertainty about the effects of rituximab in lupus nephritis because the certainty of the evidence is very low, probably leads to important adverse effects, and has high cost. Rituximab should not be used outside the context of a clinical trial, or only in cases where other treatments have failed and there are no resource constraints.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

